Patents Assigned to MINA THERAPEUTICS LIMITED
  • HNF4a saRNA compositions and methods of use
    Patent number: 11965163
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: April 23, 2024
    Assignee: MiNA Therapeutics Limited
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • C/EBP Alpha Short Activating RNA Compositions and Methods of Use
    Publication number: 20240124874
    Abstract: The invention relates to saRNAs targeting a C/EBP? transcript and therapeutic compositions comprising said saRNAs. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: December 23, 2022
    Publication date: April 18, 2024
    Applicant: MiNA Therapeutics Limited
    Inventor: Pål Sætrom
  • Stabilized saRNA Compositions and Methods of Use
    Publication number: 20240018519
    Abstract: The invention relates to modified oligonucleotides, e.g., saRNAs useful in upregulating the expression of a target gene and therapeutic compositions comprising such oligonucleotides. Methods of using the oligonucleotides and the therapeutic compositions are also provided.
    Type: Application
    Filed: April 12, 2023
    Publication date: January 18, 2024
    Applicant: MiNA Therapeutics Limited
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Vikash Reebye
  • SIRT1-saRNA Compositions and Methods of Use
    Publication number: 20240002850
    Abstract: The invention relates to a saRNAs useful in upregulating the expression of the SIRT1 gene and therapeutic compositions comprising the saRNA. Methods of using the saRNA and the therapeutic compositions are also provided.
    Type: Application
    Filed: December 21, 2022
    Publication date: January 4, 2024
    Applicant: MiNA Therapeutics Limited
    Inventors: Siv Anita Hegre, Pinelopi Andrikakou, Vikash Reebye
  • Albumin Production and Cell Proliferation
    Publication number: 20240002854
    Abstract: The present invention provides short activating RNA molecules which up-regulate albumin production. The present invention also provides methods of up-regulating albumin production, such methods involving the use of short activating RNA molecules capable of increasing the expression of albumin. The present invention also provides the use of the short activating RNA molecules in therapy, such as treating or preventing a hyperproliferative disorder and/or a disorder characterised by hypoalbuminemia.
    Type: Application
    Filed: May 12, 2023
    Publication date: January 4, 2024
    Applicant: MiNA Therapeutics Limited
    Inventor: Pål Sætrom
  • SIRT1-saRNA compositions and methods of use
    Patent number: 11566246
    Abstract: The invention relates to a saRNAs useful in upregulating the expression of the SIRT1 gene and therapeutic compositions comprising the saRNA. Methods of using the saRNA and the therapeutic compositions are also provided.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 31, 2023
    Assignee: MiNA Therapeutics Limited
    Inventors: Siv Anita Hegre, Pinelopi Andrikakou, Vikash Reebye
  • Stabilized HNF4A saRNA compositions and methods of use
    Patent number: 11447773
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: September 20, 2022
    Assignee: MINA THERAPEUTICS LIMITED
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Vikash Reebye
  • Methods of inducing insulin production
    Patent number: 11365414
    Abstract: The present invention provides a method of inducing insulin production in a cell by up-regulating a target gene involved in insulin production in said cell using an saRNA (short activating ribonucleic acid) which specifically targets a target antisense RNA transcript present in said cell.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: June 21, 2022
    Assignee: MINA THERAPEUTICS LIMITED
    Inventor: Pål Sætrom
  • HNF4A saRNA compositions and methods of use
    Patent number: 11162099
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: November 2, 2021
    Assignee: MINA THERAPEUTICS LIMITED
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • C/EBP alpha saRNA compositions and methods of use
    Patent number: 10912790
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: February 9, 2021
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Sætrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • C/EBP ALPHA SARNA COMPOSITIONS AND METHODS OF USE
    Publication number: 20200376020
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: April 21, 2016
    Publication date: December 3, 2020
    Applicant: MiNA THERAPEUTICS LIMITED
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Sætrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Methods of inducing insulin production
    Patent number: 10774331
    Abstract: The present invention provides a method of inducing insulin production in a cell by up-regulating a target gene involved in insulin production in said cell using an saRNA (short activating ribonucleic acid) which specifically targets a target antisense RNA transcript present in said cell.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: September 15, 2020
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventor: Pål Sætrom
  • Albumin production and cell proliferation
    Patent number: 10704044
    Abstract: The present invention provides short activating RNA molecules which up-regulate albumin production. The present invention also provides methods of up-regulating albumin production, such methods involving the use of short activating RNA molecules capable of increasing the expression of albumin. The present invention also provides the use of the short activating RNA molecules in therapy, such as treating or preventing a hyperproliferative disorder and/or a disorder characterised by hypoalbuminemia.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: July 7, 2020
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventor: Pål Sætrom
  • C/EBP? short activating RNA compositions and methods of use
    Patent number: 10633659
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 28, 2020
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventor: PÅL SÆtrom
  • C/EBP? short activating RNA compositions and methods of use
    Patent number: 10202601
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: February 12, 2019
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventor: Pål Sætrom
  • Albumin production and cell proliferation
    Patent number: 9944930
    Abstract: The present invention provides short activating RNA molecules which up-regulate albumin production. The present invention also provides methods of up-regulating albumin production, such methods involving the use of short activating RNA molecules capable of increasing the expression of albumin. The present invention also provides the use of the short activating RNA molecules in therapy, such as treating or preventing a hyperproliferative disorder and/or a disorder characterised by hypoalbuminemia.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: April 17, 2018
    Assignee: MINA THERAPEUTICS LIMITED
    Inventor: Pål Sætrom
  • Methods of inducing insulin production
    Patent number: 9885046
    Abstract: The present invention provides a method of inducing insulin production in a cell by up-regulating a target gene involved in insulin production in said cell using an saRNA (short activating ribonucleic acid) which specifically down-regulates a target antisense RNA transcript present in said cell, wherein (i) said target RNA transcript is complementary to a sequence located on the coding strand of the target gene between 1000 nucleotides upstream and 1000 nucleotides downstream of the transcription start site of the target gene; and (ii) said sRNA is a single or double stranded RNA molecule up to 30 nucleotides in length comprising a sequence of at least 13 nucleotides which has at least 95% complementarity to a region of the target transcript. Also provided are certain saRNA molecules and uses thereof, particular medical uses, and induced cells and uses thereof.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: February 6, 2018
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventor: Pål Sætrom
  • Albumin production and cell proliferation
    Patent number: 9745579
    Abstract: The present invention provides short activating RNA molecules which up-regulate albumin production. The present invention also provides methods of up-regulating albumin production, such methods involving the use of short activating RNA molecules capable of increasing the expression of albumin. The present invention also provides the use of the short activating RNA molecules in therapy, such as treating or preventing a hyperproliferative disorder and/or a disorder characterised by hypoalbuminemia.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: August 29, 2017
    Assignee: MINA THERAPEUTICS LIMITED
    Inventor: Pål Sætrom
  • SARNA COMPOSITIONS AND METHODS OF USE
    Publication number: 20170044540
    Abstract: The invention relates to a saRNAs useful in upregulating the expression of a target gene and therapeutic compositions comprising the saRNA. Methods of using the saRNA and the therapeutic compositions are also provided.
    Type: Application
    Filed: April 22, 2015
    Publication date: February 16, 2017
    Applicant: MINA THERAPEUTICS LIMITED
    Inventors: Pål Sætrom, Endre Bakken Stovner
  • Albumin production and cell proliferation
    Patent number: 9284553
    Abstract: The present invention provides short activating RNA molecules which up-regulate albumin production. The present invention also provides methods of up-regulating albumin production, such methods involving the use of short activating RNA molecules capable of increasing the expression of albumin. The present invention also provides the use of the short activating RNA molecules in therapy, such as treating or preventing a hyperproliferative disorder and/or a disorder characterized by hypoalbuminemia.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: March 15, 2016
    Assignee: MINA THERAPEUTICS LIMITED
    Inventor: Pål Sætrom